| Literature DB >> 32886936 |
Maria J Lizardo-Thiebaud1, Eduardo Cervantes-Alvarez2,3, Nathaly Limon-de la Rosa2, Farid Tejeda-Dominguez1, Mildred Palacios-Jimenez2,4, Osvely Méndez-Guerrero2, Marco Delaye-Martinez2,3, Fatima Rodriguez-Alvarez2,4, Beatriz Romero-Morales2, Wei-Hui Liu5, Christene A Huang6, David Kershenobich2, Nalu Navarro-Alvarez1,2,6.
Abstract
Liver injury can result from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with more than one-third of COVID-19 patients exhibiting elevated liver enzymes. Microvesicular steatosis, inflammation, vascular congestion, and thrombosis in the liver have been described in autopsy samples from COVID-19 patients. Several factors, including direct cytopathic effect of the virus, immune-mediated collateral damage, or an exacerbation of preexisting liver disease may contribute to liver pathology in COVID-19. Due to its immunological functions, the liver is an organ likely to participate in the viral response against SARS-CoV-2 and this may predispose it to injury. A better understanding of the mechanism contributing to liver injury is needed to develop and implement early measures to prevent serious liver damage in patients suffering from COVID-19. This review summarizes current reports of SARS-CoV-2 with an emphasis on how direct infection and subsequent severe inflammatory response may contribute to liver injury in patients with and without preexisting liver disease. Thieme. All rights reserved.Entities:
Mesh:
Year: 2020 PMID: 32886936 DOI: 10.1055/s-0040-1715108
Source DB: PubMed Journal: Semin Liver Dis ISSN: 0272-8087 Impact factor: 6.115